Company description

On December 1, 2025, Apimeds Pharmaceuticals US, Inc., a Delaware corporation (“ APUS ”, the “ Company,” “ we,” “ us,” or “ our ”) entered into and closed an Agreement and Plan of Merger (the “ Merger Agreement ”), with Apimeds Merger Sub, Inc., a Delaware corporation (“ Merger Sub ”), MindWave Innovations Inc, a Delaware corporation (“ MindWave ”), Lokahi Therapeutics, Inc., a Nevada corporation (“ Bio Sub ”), and Erik Emerson, solely in his capacity as representative for the Bio Business (the “ Bio Business Representative ”). The transactions contemplated by the Merger Agreement are referred to herein as the “ Transactions ” and the closing of the Transactions is referred to herein as the “ Closing ”. Pursuant to the terms and conditions of the Merger Agreement, immediately prior to the Closing, a certificate of merger (the “ Certificate of Merger ”) was filed with the Secretary of State of the State of Delaware (the “ DE SOS ”) (such time of the filing of the Certificate of Merger, the “ Effective Time ”), in accordance with the DGCL. Pursuant to the Certificate of Merger, Merger Sub was merged with and into MindWave (the “ Merger ”), with MindWave surviving the Merger as the surviving corporation (the “ Surviving Corporation ”). As a result of the Merger, MindWave became a direct wholly owned subsidiary of the Company.

Read the full filing description · filed 4 May 2026

At a glance

Sector

Healthcare

Industry

Pharmaceutical Preparations

CEO

Dr. Vin Menon

Incorporated in

DE

Sector is derived from the SEC industry classification.